Etiology and Audiological Outcomes at 3 Years for 364 Children in Australia

Abstract

Hearing loss is an etiologically heterogeneous trait with differences in the age of onset, severity and site of lesion. It is caused by a combination of genetic and/or environmental factors. A longitudinal study to examine the efficacy of early intervention for improving child outcomes is ongoing in Australia. To determine the cause of hearing loss in these children we undertook molecular testing of perinatal “Guthrie” blood spots of children whose hearing loss was either detected via newborn hearing screening or detected later in infancy. We analyzed the GJB2 and SLC26A4 genes for the presence of mutations, screened for the mitochondrial DNA (mtDNA) A1555G mutation, and screened for congenital CMV infection in DNA isolated from dried newborn blood spots. Results were obtained from 364 children. We established etiology for 60% of children. One or two known GJB2 mutations were present in 82 children. Twenty-four children had one or two known SLC26A4 mutations. GJB2 or SLC26A4 changes with unknown consequences on hearing were found in 32 children. The A1555G mutation was found in one child, and CMV infection was detected in 28 children. Auditory neuropathy spectrum disorder was confirmed in 26 children whose DNA evaluations were negative. A secondary objective was to investigate the relationship between etiology and audiological outcomes over the first 3 years of life. Regression analysis was used to investigate the relationship between hearing levels and etiology. Data analysis does not support the existence of differential effects of etiology on degree of hearing loss or on progressiveness of hearing loss.

Introduction

Permanent childhood hearing loss, which occurs in 1–2 per 1000 live births [1], is associated with significant under-achievement in education and lifetime costs of care and lost productivity [2]. Universal newborn hearing screening (UNHS) has been adopted in many regions as a means to speed diagnosis and intervention. Despite its widespread implementation, the available evidence on whether earlier intervention improves long-term speech and language outcomes is flawed in important ways, including cohort composition and potential for systematic bias (reliance on parent-report measures only, non-blinded assessment, and selective follow up) [3]. To address the question of whether, at a population level, UNHS is effective in reducing the gap in speech and language skills between hearing-impaired children and their normal-hearing peers, we conducted the Longitudinal Outcomes of Children with Hearing Impairment (LOCHI) study to directly compare outcomes of children with or without access to UNHS in a prospective manner. The existence of uniform auditory intervention for all hearing-impaired children in Australia, within the government-funded national service provision system (Australian Hearing), serves to minimize variables that might affect outcomes.

Childhood hearing loss is an etiologically heterogeneous condition, caused by environmental factors and/or genetic factors. Despite this heterogeneity, mutations in the GJB2 (connexin 26, Cx26) gene, the SLC26A4 (pendred) gene and in the mitochondrial DNA at position 1555 (A1555G mutation) and congenital cytomegalovirus (CMV) infection have been considered as the major causes of congenital hearing loss in developed countries [4]. No previous population-based longitudinal studies on child outcomes have examined etiologies and related these to audiological outcomes in the same cohort. We have performed molecular testing for the four common causes to determine the frequency of occurrence in a community sample, and examined the relationship between etiology and audiological outcomes of children over their first 3 years of life. We hypothesized that there will be no difference in hearing level between children with known etiologies and children with none of the etiologies (Hypothesis 1). We also hypothesized that there will be no difference in progression of hearing loss over the first 3 years of life between children with known etiologies and children with none of the tested etiologies (Hypothesis 2).

Subjects and Methods

Ethics Statement

The study was approved by institutional ethics review boards (Royal Children’s Hospital HREC 28055 and Australian Hearing HREC 2008-3).

Subjects

The LOCHI study commenced in 2005, with recruitment completed in 2007. All families with children born in Australia between 2002 and 2007 and who presented for hearing services below 3 years of age at Australian Hearing (AH) were invited to participate. Parents of children enrolled in the LOCHI study provided written, informed consent to participate. All participants were invited to give additional informed consent for molecular testing. Of the 451 eligible children, written consent was obtained for 387 children for molecular testing. There was no significant difference in hearing loss (average of 0.5, 1, 2 kHz) between the consent group and the non-consent group (p = 0.605). A total of 364 Guthrie card samples were obtained from the custodian authorities of health records. The sample comprised 280 whose hearing loss was detected via UNHS, 64 who did not have access to UNHS and 20 whose screening status was unknown.

Audiologic Assessments

In Australia, the hearing of newborns is screened using automated auditory brainstem response (AABR). Infants who do not pass hearing screening are referred for diagnostic audiological assessment. These include tympanometry, middle ear muscle reflexes, otoacoustic emissions (OAEs), click-evoked auditory brainstem response (ABR) testing, and ABR or auditory steady-state responses (ASSR) testing using frequency-specific stimuli. Following diagnosis, children are referred to AH for assessment of hearing and provision of amplification, at no cost to families. Electrophysiological tests results are converted to estimated behavioral thresholds for fitting of hearing aids [5], [6]. Behavioral hearing thresholds are obtained using visual reinforcement audiometry or conditioned play audiometry, depending on the child’s age and ability. According to national protocols, hearing levels are monitored at regular intervals by experienced AH pediatric audiologists.

Characteristics of Hearing Loss

The hearing thresholds of participants from inception to 44 months of age were retrieved from clinical records held at the AH national database, with written permission from parents. Hearing thresholds at 0.25, 0.5, 1, 2, and 4 kHz for each ear were obtained. These audiometric thresholds were used to characterize evolution of children’s hearing loss over the first 3 years of life as fluctuating, progressive, or stable. In accordance with the audiological protocol of AH, fluctuating hearing loss is defined as a change in hearing threshold of 15 dB or greater at any octave frequency between 0.5 and 4 kHz, but subsequently recover over the period of investigation. Progressive hearing loss is defined as a decrease in 10 dB or greater at two or more adjacent frequencies between 0.5 and 4 kHz or a decrease in 15 dB at one octave frequency in the same frequency range over the period of investigation. Longitudinal audiograms that do not demonstrate the changes specified above are labeled as stable.

ANSD is characterized by a dysfunction in neural/brainstem transmission of auditory stimuli in the presence of normal cochlear outer hair cell function. The clinical presentation is an absent or abnormal ABR responses and the presence of otoacoustic emissions or cochlear microphonics.

Information about enlarged vestibular aqueduct (EVA) was obtained from clinical records held at the AH national database. The diagnosis of EVA was based on CT scan. Radiographic imaging was not part of routine clinical service offered to children identified with hearing loss.

Etiologic Evaluation

Lysates for molecular screening were prepared from Guthrie blood spots, using a modification of the method described by Barbi et al. [7]. Briefly, 3 mm diameter disks were punched from the Guthrie blood spot and soaked in 100 µl lysis buffer (50 mM Tris-HCl (pH 8.5); 50 mM NaCl; 2.5 mM MgCl₂; 1 mg/ml Proteinase K; 1% Tween-20) at 56°C for 1 hour. Following incubation at 100°C for 7 mins. the samples were rapidly cooled on ice. The samples were centrifuged (10 minutes at 10,000 rpm) and the supernatants frozen for >4 hours at −80°C.

Lysates were screened for mutations in the coding region of GJB2 (exon 2) and the splice site mutation in intron 1 (IVS1+1 G>A). Exon 2 PCR products were sequenced in both directions. The IVS1+1 G>A mutation was screened for by Hph1 digestion of a PCR product which spans the splice site. If a single mutation in GJB2 was found, connexin-30 deletions del(GJB6-D13S1830) and del(GJB6d13s1854) were screened for as described by Castillo et al. [8].

Each of the SLC26A4 gene exons was PCR amplified. Following nested PCR, the products were analyzed by High Resolution Melt (HRM) on the Corbett Rotorgene 6000 (Corbett Life Science, Australia). Primary PCR products were sequenced when HRM variants were identified.

We used in silico approaches to assess if unreported changes in the GJB2 and SLC26A4 genes are likely to affect protein function: PolyPhen-2 [9], SIFT BLink and SIFT Sequence [10].

The mitochondrial 12S rRNA A1555G mutation introduces a HaeIII restriction enzyme site. PCR products were digested with HaeIII and analyzed by agarose gel electrophoresis.

The presence of CMV DNA was determined in a multiplex, quantitative, real-time PCR assay, using the CMV and CPOL probes published in Sanchez et al. [11] with the probes labelled as described in Scanga et al. [12]. Fifteen µl DNA lysate isolated from a disk was used in the PCR reaction, allowing two real-time PCR reactions to be analyzed from each 3 mm disk. The CMV tests were replicated on a second disk.

Analysis

The results are summarized as means and percentages. To investigate the relationship between etiology and hearing thresholds at 3 years of age (Hypothesis 1), multiple regression analysis was carried out using the four-frequency average hearing loss (4FAHL, average of hearing threshold levels at 0.5, 1, 2, and 4 kHz in the better ear at 3 years of age) as dependent variable and etiology as a predictor variable. To determine the evolution of hearing loss, children were grouped according to the AH national protocols into those with fluctuating, progressive, or stable hearing loss. To consider the relation between progression of hearing loss and etiology (Hypothesis 2), a mixed-effects model was fitted using the longitudinal 4FA HL (four frequency average (average of 0.5, 1, 2, and 4 kHz) hearing level) data as dependent variable, the fixed effects were age (continuous variable), the seven etiologies (one mutation for GJB2, two mutations for GJB2, one mutation for SLC26A4 gene, two mutations for SLC26A4 gene, CMV infection, enlarged vestibular aqueduct (EVA), conductive loss) as two-category predictors, and the interactions between etiologies and age. We used two-tailed tests for all analyses and set statistical significance at p<0.05. The statistical analysis was performed using Statistica (Statsoft Inc, 2005) and R [13] with the additional packages ggplot2 [14] and nlme [15].

Results

We use the wording “reported mutations” for DNA and protein changes classified as causative mutations in Cx26 and SLC26A4 mutation databases [16], [17], [18]. DNA changes with uncertain consequence on hearing are referred to as “ambiguous changes”.

Figure 1 shows the distribution of predicted diagnoses. Reported mutations or congenital CMV infection were identified in 135 (37%) children, and ambiguous changes in the GJB2 or SLC26A4 gene were detected in 31 (9%) children. We did not detect mutations or ambiguous changes or evidence of congenital CMV infection in 198 (54%) children. These findings were supplemented by information retrieved from clinical records and parental reports. The cause of hearing loss remained unknown for 146 children (40%).

Figure 1. Results of the search for hearing loss etiology in 364 Australian children.

Reported mutations of GJB2 were present in 82 children. Of these, 48 (58.5%) had two known mutations and 35 (41.5%) children had one mutation. The inheritance is in all cases compatible with a recessive inheritance pattern. Details of mutations and the evolution of hearing loss for individual children are shown in Table S1. Stable, fluctuating and progressive hearing losses are associated with GJB2 mutations, but specific genotypes do not appear to be exclusively associated with a phenotype. We assume that the hearing loss in children with two known mutations is attributable to GJB2. Of the children with two mutations of Cx26, one child passed hearing screening at birth, but was diagnosed with moderate hearing loss at 19.4 months of age. Another child was diagnosed with auditory neuropathy spectrum disorder (ANSD), and two children had EVA. Ambiguous changes in the GJB2 gene were detected in 24 children, 22 of whom have one mutation and the remaining 2 have two mutations.

Reported mutations of SLC26A4 [17], [18] were found in 24 children. Of these, seven (29.2%) had two known mutations, one of whom was also positive for CMV infection. Seventeen (70.8%) children carried one known SLC26A4 mutation, two of whom also carried one uncertain mutation and four others also carried GJB2 mutations. For 8 other children, one ambiguous change of the SLC26A4 gene was detected. Details of mutations and evolution of hearing thresholds are shown in Table S2.

Mutations in the SLC26A4 gene are associated with Pendred syndrome (PS, MIM 274600) and non-syndromic enlarged vestibular aqueduct (EVA, MIM 600791). Three children who carried one mutation of SLC26A4 also had EVA, and one child who carried two mutations of SLC26A4 also had EVA. EVA was also found for 4 children who had Cx26 mutations, 1 who had CMV infection, and 8 who had normal results for the four causes tested. The number of children who had EVA could not be ascertained because information was available only for those with imaging results recorded in their clinical files.

The mtDNA A1555G mutation was detected in one child. The mutation appeared homoplasmic on agarose gel electrophoresis. The child has bilateral ANSD with profound hearing loss. It is not known whether the child had been exposed to aminoglycosides.

Cytomegalovirus infection was detected in 28 children. Of these, one child passed UNHS but was diagnosed with meningitis and hearing loss at 5.1 months of age. A second child with congenital CMV infection also had one mutation of Cx26, and was referred for unilateral hearing loss after screening. One CMV positive child also carried two mutations of the SLC26A4 gene. Details of the evolution of hearing loss for children who are CMV positive are presented in Table S3.

In the regression analysis examining the relation between etiology and hearing threshold levels at 3 years of age, the overall p-level for the regression model was 0.27. Table 1 shows the estimate and 95% confidence interval for the regression coefficients. For each of the etiologies tested, there was insufficient evidence at the 5% significance level to reject the null hypothesis that the average hearing loss (4FA HL) for children with that etiology is the same as children without the etiology.

Table 1. Multiple regression analysis of hearing loss at 3 years of age with respect to etiology.

Predictor	Estimate	95% CI	p-value
Cx26, one mutation	−7.8	(−20.8, 5.1)	0.23
Cx26, two mutations	7.4	(−3.3, 18.1)	0.17
SLC26A4, one mutation	−7.0	(−21.0, 7.0)	0.32
SLC26A4, two mutations	−3.4	(−34.8, 27.9)	0.83
CMV	9.9	(−3.9, 23.8)	0.16
EVA	0.2	(−14.9, 15.3)	0.98
Conductive	−7.2	(−29.8, 15.3)	0.53

The estimated effect size, 95% confidence interval (CI), and the probability level (p-value) for each predictor term are shown.

Table 2 shows the estimates of the effect of etiology on progression of hearing loss over the first 3 years of life. For each of the seven etiologies investigated, there was insufficient evidence at the 5% significance level to reject the null hypothesis that the average rate of change of 4FA HL in the better ear for children with that etiology is the same as children without the etiology.

Table 2. Progression of hearing loss over the first 3 years of life, expressed in terms of slope in dB/year, with respect to predictors.

Predictor	Estimate	95% CI	p-value
Age	1.99	(−0.42, 4.41)	0.11
Cx26, one mutation×Age	−2.22	(−6.31, 1.87)	0.29
Cx26, two mutations×Age	1.12	(−2.38, 4.61)	0.53
SLC26A4, one mutation×Age	2.52	(−1.80, 6.84)	0.25
SLC26A4, two mutations×Age	0.18	(−8.11, 8.47)	0.97
CMV×Age	2.57	(−2.01, 7.15)	0.27
EVA×Age	3.97	(−0.64, 8.58)	0.09
Conductive×Age	−3.71	(−9.53, 2.11)	0.21

The estimated effect size, 95% confidence interval (CI), and the probability level (p-value) for each predictor term are shown.

Discussion

The incidence of permanent childhood hearing loss is 1 to 1.2 per 1000 at birth increasing to about 1.5 by 3 years of age [19] in Australia where compliance with confirmatory testing after hearing screening is excellent and loss to follow-up for intervention is below 1%. As a sub-component of the LOCHI study, the present study conducted molecular testing of dried newborn blood spots for GJB2, SLC26A4, A1555G and CMV infection, and established a likely etiologic diagnosis for 166 (45.6%) of the 364 cases tested. Of the causes identified, a genetic cause was present in 138 children (83.1%) and an environmental cause in 28 children (16.9%).

It has previously been suggested that hearing loss attributable to congenital CMV may be progressive in >50% of cases [20]. However, we did not find this trend when examining hearing level data of children from diagnosis to 3 years of age. Whether the progression extends beyond this young age will be revealed in future follow-ups within the context of the LOCHI study. It is possible that some children with progressive hearing loss had congenital CMV infection that was not detected, as the use of Guthrie blood spot DNA in CMV testing may result in false negatives [21]. Dilution studies suggest that our CMV assay will detect the presence of a few copies of CMV DNA present in the 15 µl lysate used in the PCR reaction. Even with such sensitivity, CMV levels might be too low to be detected in Guthrie blood cards. More sensitive is the detection of CMV virus in the newborn’s blood, saliva urine or other tissues or body fluids within 2–3 weeks of birth. However, such tissues or fluids were not available in this cohort. Our finding that 8% of blood spots were positive for CMV is likely to be an underestimation of the true number of newborn Australian children with a congenital CMV infection. This frequency of infection is indeed lower than the 18.8% (9 of 48 infants with hearing loss) at a tertiary center of UNHS in Flanders [22]. In that study, CMV was detected through PCR assays with the blood spots on Guthrie cards, viral cultures, or blood serological tests. The present findings are nonetheless consistent with those reported by Stehel et al for infants at a hospital in the US showing that 6% (16 of 256 infants with hearing loss) were CMV positive through urine cultures [23]. Even though hearing loss in children with congenital CMV infection is likely to have been caused by the infection, we cannot conclude that this is the case in all children because most children with congenital CMV infection do not develop hearing loss [20].

Looking specifically at the genetic causes of hearing loss in our population (n = 138), mutations in the GJB2 gene accounted for 76.1% of the genetic cases. This frequency of occurrence is higher than the 50% previously reported for congenital, autosomal recessive, nonsyndromic, sensorineural hearing loss in the white population [24]. Consistent with previous studies on children of northern European ancestry [22], [25], the c35delG (35delG mutation) variant was the most common allele variant of GJB2, with 60 of 135 mutant alleles (44%) being 35delG. As shown in Table S1, there was a variable genotype-phenotype correlation even among children homozygous for 35delG. Our finding that progressiveness of hearing loss in children with GJB2 mutations was not significantly different from those without the mutations is consistent with previous reports [26], [27]. Unlike previous reports that revealed an association of biallellic truncating mutations (such as 35delG) with more severe loss than those with biallellic non-truncating mutations [28], our study did not reveal such a relation between mutations and hearing level.

One known mutation in the GJB2 gene was detected in 35 children. The pathogenic effect of these single mutations are uncertain, but we have attributed the hearing losses to thise GJB2 gene changes, because the proportion of children with hearing loss and one detectable recessive GJB2 mutation is significantly higher than that of the general population (approximately 1%) [29]. The pathogenic effects of a number of other changes in the GJB2 gene of 24 children are also ambiguous. We have classified the V27I and E114G changes, when together, as a mutation in accordance with the Connexins and Deafness Homepage [16]. However, recent data suggest that the V27I+E114G changes might not be pathogenic [30]. Although sometimes classified as polymorphisms [16], it is likely that M34T [28], [31], [32], [33], [34], R127H [35], [36], [37], M195V [38], [39], and I203T [40], [41] contribute to hearing loss. The V153I change is usually considered to be a polymorphism, although it has been suggested that the mutant GJB2 protein is unable to form functional gap junction channels [42]. We have previously reported the T186A change [43], but the pathogenicity of this change has not been established. The T186A change was seen in two affected siblings together with the 35delG mutation. PolyPhen-2, SIFT BLink and SIFT Sequence analyses all predict this change to affect protein function (Table S4). The K108N change has not been reported before, but the in silico analysis suggests that is unlikely to cause hearing loss. Although SIFT Sequence analysis predicts that it is “likely to affect protein function”, PolyPhen-2 and SIFT BLink predict it is benign (Table S4).

Previous studies have shown the presence of two SLC26A4 mutations in many patients with Pendred syndrome, whereas one mutation is common in patients with EVA [44], [45] SLC26A4 mutations [17], [18] were found in 32 children. Of these, 7 (21.9%) had two known mutations, 17 (53.1%) had one known mutation and 8 (25.0%) had one uncertain mutation. As shown in Table S2, there was a complex genotype-phenotype correlation. The c.919_936delinsCCCCA change has not been described before, but the exon 8 mutation results in a frameshift and premature termination of the protein. As with the GJB2 mutations, the pathogenic effects of some of the SLC26A4 changes haven’t been fully established and are controversial. This is the case for L597S [45], [46], [47], [48], [49], [50], [51], [52], IVS1-2A>G [51], and F335L [45]. PolyPhen-2 and SIFT Sequence predict the L597S and F335L changes are “probably damaging”, while SIFT BLink suggests they affect protein function (Table S4). Only 4 of the cases identified with one or two mutations in the SLC26A4 also had EVA. The status for the remaining cases could not be ascertained from clinical records. Therefore, the pathogenicity of detected mutations in those with one mutation is uncertain.

We detected 3 previously unreported missense changes: R43H, R79Q and S780F. A mutation, R43S, has been reported in R43 suggesting that this amino acid might be important for protein function [17]. R43 and R79 are both highly conserved amino acids suggesting that the R43H and R79Q changes might affect SLC26A4 function. However, PolyPhen-2, SIFT BLink and SIFT Sequence analyses predict the R43H change to be benign. PolyPhen-2 predicts the R79Q change to be “probably damaging” to protein function, while the two SIFT programs predict that the change is “tolerated” (Table S4). Despite being the C-terminal amino acid, S780 is conserved in most species. However, in the Common Shrew (Sorex araneus) the corresponding amino acid is a phenylalanine. This suggests that the S780F change might be a polymorphism. PolyPhen-2 predicts this change to be benign, while SIFT BLink and SIFT Sequence predict that the change affects protein function (Table S4). However, the in silico predictions at the C-terminal amino acid are with low confidence because only short sequence regions can be compared.

To assess the contribution of single mutations in the GJB2 or SLC2A4 gene to a hearing loss is challenging. The study by Wang et al [53] in which 14,913 newborn Chinese children had both a newborn hearing test and a genetic screen for GJB2 and SLC2A4 mutations showed significantly increased risks of hearing loss in GJB2 and SLC2A4 heterozygous carrier children.

The A1555G mtDNA mutation increases susceptibility to aminoglycoside induced hearing loss. Because many newborns and young children are exposed to aminoglycoside antibiotics, its potential presence is often of concern to health professionals and families. The A1555G mtDNA mutation was found in only one of the 364 hearing-impaired children. Our result is consistent with previous observations that this mutation is not a common cause of hearing loss in children less than 3 years of age in the general Australian population. [43].

A diagnosis of ANSD was established for 39 children. Of the children diagnosed with ANSD, four had one SLC26A4 mutation also; six had one GJB2 mutation and one child had two GJB2 mutations. Twenty-six of the children with ANSD did not have detectable mutations or evidence of CMV infection. The presence of ANSD results in degraded oral language development.

The limitations of this study include its reliance on newborn blood spots for CMV testing. Supplementing UNHS with molecular testing would enable pre-symptomatic detection of preventable hearing loss for some children. Despite testing for four common causes of childhood hearing loss, the etiology for 54% of the cohort remains unknown. Future molecular testing for etiology of hearing loss will need to include mutations in other genes, such as OTOF, encoding otoferlin, in which mutations are commonly found in children with ANSD. It was not possible to do a comprehensive audiological and genetic study of parents, siblings and other relatives of affected children. Such study could be helpful in assessing the inheritance and consequence of a GJB2 or SLC26A4 change. Future follow-up of the present cohort as part of the longitudinal study will examine the relation between an identified genetic/viral cause and the type and degree of hearing loss as the children grow.

The strengths of the LOCHI study include its longitudinal, community-based design, with prospective, repeated measurements of hearing and developmental outcomes. The longer term audiological outcomes of children with different etiologies will be evaluated.

Conclusion

This study presents the first comprehensive evaluation of four common causes of childhood hearing loss in a community cohort. After etiologic evaluation of 364 children identified with hearing loss below 3 years of age, a genetic diagnosis could be made in 46% of those children. Approximately another 14% of children had clinical abnormalities or syndromes without identified GJB2 or SLC26A4 mutations. Our findings provide a basis for future studies to determine the impact of mutations of the GJB2 and SLC26A4 genes and congenital CMV infection on speech and language outcomes in children with hearing loss. Establishing the etiology of an identified hearing loss provides answers to parents, facilitates planning of hearing loss management and provides information that is relevant to the prognosis for the child.

Supporting Information

Table S1

Genotype-phenotype correlation in children with GJB2 mutations and evolution of hearing loss.

(DOC)

Table S2

Genotype-phenotype correlation in children with SLC26A4 mutations and evolution of hearing loss. Children with SLC26A4 mutations with additional diagnostic information regarding enlarged vestibular aqueduct (EVA), auditory neuropathy spectrum disorder (ANSD) and congenital cytomegalovirus infection (CMV) are also indicated.

(DOC)

Table S3

Hearing thresholds at time of diagnosis and evolution in children with hearing loss attributable to congenital CMV infection.

(DOC)

Table S4

PolyPhen-2, SIFT BLink and SIFT Sequence predictions of novel or controversial amino acid changes on GJB2 and SLC26A4 gene product functions.

(DOCX)

Funding Statement

The project described was partly supported by Award Number R01DC008080 from the National Institute on Deafness and Other Communication Disorders. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Deafness and Other Communication Disorders or the National Institutes of Health. The authors acknowledge the financial support of the Commonwealth of Australia through the establishment of the HEARing CRC and the Cooperative Research Centres Program. The authors also acknowledge the financial support of the Victorian Government’s Operational Infrastructure Support Program in Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.